Status:
COMPLETED
L-Arginine in the Treatment of Peripheral Arterial Disease
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Cardiovascular Diseases
Peripheral Vascular Diseases
Eligibility:
All Genders
Phase:
NA
Brief Summary
To assess the effects of L-arginine upon functional status (treadmill exercise testing; quality of life) and limb blood (by mercury strain gauge plethysmography) in peripheral arterial disease.
Detailed Description
BACKGROUND: Peripheral arterial disease is a common disorder effecting up to 15% of men over age 55 and women over age 65. Patients with peripheral arterial disease are at increased risk for stroke, ...
Eligibility Criteria
Inclusion
- Patients with diabetic retinopathy, active malignancy or previous malignancy in a state of remission, or autoimmune disorders will be excluded.
Exclusion
Key Trial Info
Start Date :
February 1 2000
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00284076
Start Date
February 1 2000
End Date
July 1 2006
Last Update
March 5 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.